SII chairman Cyrus Poonawalla says booster dose of Covishield desirable

The ideal gap between two doses of Covishield is two months and another dose of the vaccine should be taken after six months, the Serum Institute of India (SII) chairman Cyrus Poonawalla said here on Friday.

Asked about a report in the medical journal Lancet that antibodies against coronavirus created by Covishield, the vaccine manufactured by the SII, decrease after some time, Poonawalla told reporters that it was true that the antibodies decrease, but “memory cells” remain.

“After six months, the antibodies go down and that is why I have taken the third dose. We have given the third dose to our seven to eight thousand SII employees. For those who have completed the second dose, it is my request to take a booster dose (third dose) after six months,” he said.

He was speaking at a press conference after receiving the prestigious Lokmanya Tilak award here. The ideal gap between two doses of Covishield is two months, he said. “Since there was a shortage of vaccine, the Modi government changed it to three months, but a two-month gap is ideal,” Poonawalla said. He also said that lockdown was not an effective way to deal with the virus.

“Because if there is no lockdown, the disease will be there in the beginning but later the herd immunity will prevail. Why I prefer herd immunity is because the death rate (due to coronavirus) is very low. Lockdown is a good option when the death rate is high,” he said.

In most cases deaths were caused by negligence and delay in reporting the infection to doctors, he claimed.

  • Related Posts

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi